Derm In The News: December 3-9

University of Miami: Prurigo Nodularis Treatment Effective in Phase 3 Trial

Researchers, led by Gil Yosipovitch, MD, have conducted a phase 3 clinical trial demonstrating the effectiveness of nemolizumab, a second systemic treatment, for prurigo nodularis (PN). The trial showed that nemolizumab, a monoclonal antibody targeting the Interleukin-31 receptor, rapidly reduced itching, diminished pain, and reduced skin nodules in moderate-to-severe PN patients. The study involved 274 adults across 9 countries, with more than half of the patients experiencing relief from PN symptoms.

Westfair Business Journal: Cosmetic dermatology -- not for women only

Jeremy Brauer, MD, FAAD, founder of Spectrum Skin and Laser, is the editor and co-author of "Men’s Aesthetics: A Practical Guide to Minimally Invasive Treatment." The book covers a range of topics, addressing the aesthetic concerns of men, including those of color and transgender patients, facial aging, hair restoration, and fat and cellulite treatments. Driven by advancements in laser and light-based therapies, the demand for minimally invasive options has risen, offering natural results with minimal downtime and reduced risk.

Read Dermatology Times' interview with Jeremy Brauer, MD, FAAD, here.

Indian Express: Chandigarh’s PGI gets first skin bank, find out what it is

The Department of Plastic Surgery at PGIMER, Chandigarh, India, inaugurated the first skin bank in the northern region. The skin bank aims to address the challenges faced by burn patients, providing them with a resource for skin grafting. The establishment of the skin bank is a milestone, especially considering the shortage of skin banks in the northern region of India.

Globe Newswire: Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Journey Medical Corporation has received official meeting minutes from its pre-New Drug Application (NDA) meeting with the FDA for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) designed to treat rosacea in adults. The FDA agreed during the meeting that the proposed data package is sufficient to support the NDA submission. Journey Medical plans to submit the NDA for DFD-29 around the end of 2023, pending FDA approval. DFD-29 demonstrated positive topline data in phase 3 clinical trials, achieving all primary and secondary endpoints for the treatment of rosacea.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.